

References

References

- Abbott CA, Carrington AL, Ashe H, et al., (2003).** Incidence of, and risk-factors for, new diabetic foot ulceration in a community based patient cohort. *Diabet Med*; 19:377-384.
- Abbott, Vileikyte, Williamson, et al., (1998).** Multicenter study of the incidence and predictive risk factors for diabetic neuropathic foot ulceration. *Diabetes Care*; 21:1071–1075.
- Abbott CA, Carrington AL, Ashe H, et al., (2002).** The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. *Diabet Med*; 19:377–384.
- Abouaesha F, van Schie CH, Griffiths G et al., (2001).** Plantar tissue thickness is related to peak plantar pressure in the high-risk diabetic foot. *Diabetes Care*;24: 1270–1274.
- Adamis AP and Shima DT (2005).** The role of vascular endothelial growth factor in ocular health and disease. *Retina*; 25(2):111–118.
- Adler AL, Boyko EJ, and Ahroni JH (1999).** Lower-extremity amputation in diabetes: The independent effects of peripheral vascular disease, sensory neuropathy, and foot ulcers. *Diabetes Care*; 22:1029–1035.
- Aiello LP, Avery RL, Arrigg PG, et al (1994).** Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. *N Engl J Med* ;331: 1480–1487.
- American Diabetes Association (2003).** Peripheral Arterial Disease in People with Diabetes. *Diabetes Care*; 26:3333–3341.
- American Diabetes Association (1998).** Diagnosis of Coronary Heart Disease and Diabetes, *Diabetes Care*; 21:1551–1559.
- American Diabetes Association (1999).** Consensus development conference on diabetic foot wound care. *Diabetes Care*; 22:1354–1360.
- American Diabetes Association (2000).** Diabetic nephropathy, ADA position statement. *Diabetes Care*; 23 (Suppl 1):S69–S72.
- American Diabetes Association (2003).** Peripheral arterial disease in people with diabetes. *Diabetes Care*; 36:3333–3341.
-

References

- American Diabetes Association (2004).** Dyslipidemia management in adults with diabetes, position statement. *Diabetes Care*; 27(Suppl 1):S68–S71.
- American Diabetes Association (2004).** Hypertension management in adults with diabetes. *Diabetes Care*; 27(Suppl 1):S65–S67.
- American Diabetes Association (2005).** Standards of medical care in diabetes. *Diabetes Care*; 28:S4–S36.
- American Diabetes Association (2007).** Diagnosis and classification of diabetes mellitus. *Diabetes Care*; 30: S42-S47.
- American Diabetes Association (2010).** Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care*; 33 (Suppl. 1): S62–S6.
- Arieff AI and Carroll HJ (1972).** Non-ketotic hyperosmolar coma with hyperglycemia: clinical features, pathophysiology, renal function, acid base balance, plasma-cerebrospinal fluid equilibria, and the effects of therapy in 37 cases, *Medicine*; 51:73–94.
- Arkkila PE, Kantola IM, Viikari JS, et al., (1996).** Limited joint mobility is associated with the presence but does not predict the development of microvascular complications in Type 1 diabetes. *Diabetic Med*; 13:828–833.
- Armstrong DG and Frykberg RG (2003).** Classification of diabetic foot surgery: toward a rational definition. *Diabet Med*; 20:329-331.
- Armstrong DG and Lavery LA (1998).** Diabetic foot ulcers: prevention, diagnosis and classification. *Am Fam Phys*; 57:6:1325–1332, 1337–1338.
- Armstrong DG, Lavery LA, and Harkless LB (1998).** Validation of a diabetic wound classification system: The contribution of depth, infection, and ischemia to risk of amputation. *Diabet Med*; 21:855–859.
- Armstrong DG and Lipsky BA (2004).** Advances in the treatment of diabetic foot infections. *Diabetes Technol Ther*; 6(2):167–177.
- Armstrong DG, Salas P, et al., (2005).** Maggot therapy in “lower-extremity hospice” wound care: Fewer amputations and more antibiotic free days. *J Am Podiatr Med Assoc*; 95(3):254–257.
- Atchley D, et al., (2002).** Oxidized LDL–anti-oxidized LDL immune complexes and diabetic nephropathy. *Diabetologia*; 45:1562–157.
-

References

- Australian and New Zealand Dialysis and Transplant Registry (2000).** ANZDATA Registry. ANZDATA, Adelaide.
- Bethel MA, Sloan FA, Belsky D, et al., (2007).** Longitudinal incidence and prevalence of adverse outcomes of diabetes mellitus in elderly patients. *Archives of Internal Medicine*; 167(9): 921–927.
- Berliner J, et al., (1995).** Atherosclerosis: Basic mechanisms: Oxidation, inflammation and genetics. *Circulation*; 91:2488–2496.
- Birke JA, Franks BD, and Foto JG(1995).** First ray joint limitation, pressure, and ulceration of the first metatarsal head in diabetes mellitus. *Foot Ankle*; 16:277–284.
- Birrer RB, Dellacorte MP, and Grisafi PJ (1996).** Prevention and care of diabetic foot ulcers. *Am Fam Physician*; 53(2):601-11, 615-6.
- Bloomgarden ZT (2004).** Glycemic treatment: Control of glycemia. [Review] [40 refs]. *Diabetes Care*; 27(5):1227-34.
- Border WA and Noble NA (1998).** Evidence that TGF-beta should be a therapeutic target in diabetic nephropathy. *Kidney Int*; 54:1390–1391.
- Boulton AJ (2004).** The diabetic foot: from art to science. The 18th Camillo Golgi lecture. *Diabetologia*.
- Boulton AJ (1992).** Peripheral neuropathy and the diabetic foot. *Foot*; 2:67 72.
- Boulton AJ (2000).** The diabetic foot: a global view. *Diabetes Metab Res Rev*; 16(1):S2-5.
- Boulton AJ (2002).** Risk of diabetes-related amputation in South Asians vs Europeans in the UK. *Diabet Med*; 19:99-104.
- Boulton AJ, Armstrong DG, Albert SF, et al., (2008).** Comprehensive foot examination and risk assessment. *Diabetes Care*; 31:1679–1685.
- Boulton AJM, Kirsner RS, and Vileikyte L (2004).** Clinical practice. Neuropathic diabetic foot ulcers. *N Engl J Med*; 351:48-55.
- Boulton AJM, Malik RA, Arezzo JC, et al., (2004).** Diabetic somatic neuropathies. *Diabetes Care*; 27:1458–1486.
- Boulton AJ, Vileikyte L, Ragnarson, et al., (2005).** The global burden of diabetic foot disease. [Review] [75 refs]. *Lancet*; 366 (9498):1719-24.
-

References

- Boulton AJM, Vinik, AI, Arezzo, J, et al., (2005).** Diabetic neuropathies: A statement by the American Diabetes Association. *Diabetes Care*; 28:956- 962.
- Bowler PG (2002).** Wound pathophysiology, infection and therapeutic options. *Ann Med*; 34(6):419–427.
- Bowler PG (2003).** The bacterial growth guideline: Reassessing its clinical relevance in wound healing. *Ostomy Wound Management*; 49(1):44 53.
- Bowler PG, Duerden BI, et al (2001).** Wound microbiology and associated approaches to wound management. *Clin Microbiol Rev*; 14(2):244–269.
- Boyko EJ and Afroni JF (1996).** Predictors of transcutaneous oxygen tension in the lower limbs of diabetic subjects. *Diabet Med*; 13:549–554.
- Boyko EJ, Ahroni JH, Cohen V, et al., (2006).** Prediction of diabetic foot ulcer occurrence using commonly available clinical information: The Seattle Diabetic Foot Study. *Diabetes Care*; 29(6):1202–1207.
- Brash PD, J Foster, Vennart W, et al., (1999).** Magnetic resonance imaging techniques demonstrate soft tissue damage in the diabetic foot. *Diabetic Med*; 16: 55–61.
- Bridges RM and Deitch EA (1994).** Diabetic foot infections: Pathophysiology and treatment. *Surg Clin North Am*; 74:537–555.
- Brownlee M (1995).** The pathological implications of protein glycation. *Clin InvestMed*; 18: 275–281.
- Brownlee M (2005).** The pathobiology of diabetic complications: a unifying mechanism. *Diabetes*; 54(6):1615–1625.
- Brownlee M, Vlassara H, and Cerami A (1985).** Non-enzymatic glycosylation products on collagen covalently trap low-density lipoprotein. *Diabetes*; 34:938–941.
- Bucala R, Cerami A, and Vlassara H (1995).** Advanced glycosylation end products in diabetic complications. Biochemical basis and prospects for therapeutic intervention. *Diabetes Rev*; 3:258–268.
- Bucala R, Tracey KJ, and Cerami A (1991).** Advanced glycosylation products quench nitric oxide and mediate defective endothel-

References

- um dependent vasodilatation in experimental diabetes. *J Clin Invest*; 87:432–438.
- Bucala R and Vlassara H (1995).** Advanced glycosylation end products in diabetic renal and vascular disease. *Am J Kidney Dis*; 26:875–888.
- Bus SA, Yang QX, Wang JH, et al., (2002).** Intrinsic muscle atrophy and toe deformity in the diabetic neuropathic foot. A magnetic resonance imaging study. *Diabetes Care*; 25:1444–1450.
- Buse JB (1999).** The patient with Diabetes, in *Management of Office Emergencies* (Barton CW, ed) McGraw Hill, New York, pp. 73–95.
- Buse JB and Polonsky KS (1998).** Diabetic ketoacidosis, hyperglycemic hyperosmolar nonketotic coma, and hypoglycemia, in *Principles of Critical Care Medicine* (Hall JBM, Schmidt GA, Woods LDH, eds). 2nd ed., McGraw Hill, New York, pp. 1183–1193.
- Cameron NE, Cotter MA, Archbald V, et al., (1994).** Anti-oxidant and pro-oxidant effects on nerve conduction velocity, endoneurial blood flow and oxygen tension in non-diabetic and streptozotocin diabetic rats. *Diabetologia*; 37:449–459.
- Cameron NE, Cotter MA, Lai K, et al., (1997).** Effects of protein kinase C inhibition on nerve function, blood flow and Na⁺, K⁺ ATPase defects in diabetic rats. *Diabetes*; 46 (Suppl. 1):31A.
- Cameron NE, Eaton SE, Cotter MA, Tesfaye S (2001).** Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. *Diabetologia*; 44:1973–1988. neuropathy in patients with different syndromes of diabetic polyneuropathy. *Diabetes*; 35:192–197.
- Cannon CP, Braunwald E, McCabe CH, et al., (2004).** Pravastatin or atorvastatin evaluation and infection therapy thrombolysis in MI 22 investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med*; 350(15): 1495–1504.
- Capsaicin Study Group (1992).** The effect of treatment with capsaicin on daily activities of patients with painful diabetic neuropathy. *Diabetes Care*; 15:159–165.
- Carbayo JA, Divison JA, Escribano J, et al., (2007).** Using ankle-brachial index to detect peripheral arterial disease: prevalence
-

References

- and associated risk factors in a random population sample. *Nutr Metab Cardiovasc Dis*; 17(1): 41–9.
- Cavanagh PR, Boulton AJ, Sheehan P, et al., (2002).** Therapeutic foot wear in patients with diabetes. *JAMA*; 288:1231.
- Centers for Disease Control and Prevention:** History of foot ulcer among persons with diabetes: United States, 2000–2002. *MMWR Morb Mortal Wkly Rep*; 52(45):1098–1102.
- Chaturvedi N, Abbott CA, Whalley A, et al., (2002).** 5 questions and answers about maggot debridement therapy. *Adv Skin Wound Care*; 16 (2):99–102.
- Claxton MJ, Armstrong DG, et al (2003):** 5 questions and answers about maggot debridement therapy. *Adv Skin Wound Care* 16(2):99–102
- Clinical practice recommendations (2005).** *Diabetes Care*, 28 (supp, 1).
- Cohen MM, et al., (2001).** Osteomyelitis in the diabetic patient: Diagnosis and treatment. Part 2: Medical, surgical, and alternative treatments. *Ostomy Wound Manage*; 47(3):24–30, 32–41; quiz 42–43.
- Colhoun HM, Betteridge DJ, Durrington PN, et al., (2004).** CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. *Lancet*; 364(9435):685–696.
- Cowie CC, FORD ES, Rust KF, et al., (2010).** Prevalence of diabetes and high risk for diabetes using Hb A1C criteria in The U S. *Diabetic care*, 33:562-568.
- Cowie CC, Port FK, Wolfe RA, et al., (1989).** Disparities in incidence of diabetic end-stage renal disease according to race and diabetes. *N Engl J Med*; 321:1074–1079.
- Cranston I, Lomas J, Maran A, et al., (1994).** Restoration of hypoglycaemia awareness in patients with long duration insulin-dependent diabetes. *Lancet*; 344:283–287.
- Cruciani M, Lipsky BA, et al., (2005).** Are granulocyte colony-stimulating factors beneficial in treating diabetic foot infections?: A meta analysis. *Diabetes Care*; 28(2):454–460.
-

References

- Dandona P, Aljada A, Chaudhuri A, et al., (2004).** Endothelial dysfunction, inflammation and diabetes. *Rev Endocr Metab Disord*; 5(3):189–197.
- Davies MJ, et al., (1993).** The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. *J Pathol* 171:223.
- DCCT (Diabetes Control and Complications Trial) Research Group (1995).** The effect of intensive diabetes therapy on the development and progression of neuropathy. *Ann Intern Med*; 122:561–568 .
- Dinh TL and Veves A (2005).** A review of the mechanisms implicated in the pathogenesis of the diabetic foot. [Review] [37refs]. *International Journal of Lower Extremity Wounds*; 4(3):154-9.
- Doi T, et al., (1992).** Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. *Proc Natl Acad Sci U S A*; 89:2873–2877.
- Dyck P (1988).** Detection, characterization, and staging of polyneuropathy: Assessed in diabetics. *Muscle Nerve*; 11:21–32.
- Dyck PJ, Karnes J, and O'Brien PC (1987).** Diagnosis, staging, and classification of diabetic neuropathy and associations with other complications. In Dyck PJ, Thomas PK, Asbury AK, et al (eds): *Diabetic Neuropathy*. Philadelphia: WB Saunders; pp 3644.
- Dyck PJ, Kratz KM, Karnes JL, et al., (1993).** The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study [erratum in *Neurology*; 43:2345].
- Dyck PJ, Zimmerman BR, Vilan TH., et al (1988).** Nerve glucose, fructose, sorbitol, myoinositol, and fiber degeneration in diabetic neuropathy. *N Engl J Med*; 319:542–548.
- Edelson GW, Armstrong DG, Lavery LA, et al., (1996).** The acutely infected diabetic foot is not adequately evaluated in an inpatient setting. *Arch Intern Med*; 156:2373–2378.

References

- Eke CC, Bunt TJ, and Killeen JD (1995).** A prospective evaluation of transcutaneous oxygen measurements in the management of diabetic foot problems. *J Vasc Surg*; 22(4):485–490.
- Eneroth M, Larsson J, and Apelqvist J (1999).** Deep foot infection in diabetes mellitus: An entity with different characteristics, treatment and prognosis. *J Diabetic Complications*; 13:254–263.
- England, J. D., Gronseth, G. S., Franklin, G., et al., (2005).** Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. *Neurology*; 64(2), 199–207.
- Erkkil. AT, et al., (2000).** Autoantibodies against oxidized low density lipoprotein and cardiolipin in patients with coronary heart disease. *Arterioscl Thromb Vasc Biol*; 20:204–209.
- Esposito C (1989).** Endothelial receptor-mediated binding of glucose modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. *J Exp Med*; 170:1387–1407.
- Falk E (1992).** Why do plaques rupture? *Circulation*; 86(suppl III): III-30–III-42.
- Feldman EL (2006).** Classification of diabetic neuropathy. Up To Date: Classification of diabetic neuropathy. <http://www.utdol.com>, accessed April.
- Fong DS, Aiello L, Gardner TW, et al., (2004).** Retinopathy in diabetes. *Diabetes Care*; 27(Suppl 1):S84–S87. foot ulceration. *J Wound Care*; 8:530-532.
- Gibbons GW (2003).** Lower extremity bypass in patients with diabetic foot ulcers. *Surg Clin North Am*; 83:659-669.
- Gibbons GW and Habershaw GM (1995).** Diabetic foot infections: Anatomy and surgery. *Infect Dis Clin North Am*; 9:131–142.
- Franklin, Kahn L. B., Baxter J, et al., (1998).** Sensory neuropathy in non-insulin-dependent diabetes mellitus. The San Luis Valley Diabetes Study. *Am J Epidemiol* 131(4), 633–643.
- Frier BM (2008).** How hypoglycaemia can affect the life of a person with diabetes. *Diabetes Metab Res Rev*; 24(2): 87-92.
-

References

- Frykberg RG (2005).** A summary of guidelines for managing the diabetic foot. *Adv Skin Wound Care*; 18: 209–14.
- Frykberg RG (2003).** Diabetic foot ulcerations: management and adjunctive therapy. *Clin Podiatr Med Surg*; 20:709-728.
- Frykberg RG (2002).** Diabetic foot ulcers: pathogenesis and management. *Am Fam Physician*; 66:1655-1662.
- Frykberg RG, Habershaw G, and Chrzan J.S (1998).** Epidemiology of the diabetic foot: ulcerations and amputations. In: *Contemporary Endocrinology : Clinical Management of Diabetic Neuropathy*, p. 273, edited by A Veves, Humana Press, Totowa, NJ.
- Frykberg RG, Lavery LA, Pham H, et al., (1998).** Role of neuropathy and high foot pressures in diabetic foot ulceration. *Diabetes Care* ;21:1714–1719.
- Funk C and Young G (2001).** Subtotal pedal amputations. Biomechanical and intraoperative considerations. [Review] [43 refs]. *Journal of the American Podiatric Medical Association* 91(1):6-12.
- Gentry LO (1993).** Diagnosis and management of the diabetic foot ulcer. *J Antimicrob Chemother*; 32(Suppl A):77-89.
- Gilron I, Bailey JM, Tu D, et al., (2005).** Morphine, gabapentin, or their combination for neuropathic pain. *N Engl J Med*; 352(13):1324–1334.
- Gisinger C, Virella GT and Lopes-Virella MF (1991).** Erythrocyte-bound low density lipoprotein (LDL) immune complexes lead to cholesterol ester accumulation in human monocyte derived macrophages. *Clin Immunol Immunopathol*; 59:37–52.
- Giurini JM and Lyons TE (2005).** Diabetic foot complications: diagnosis and management. [Review] [84 refs]. *International Journal of Lower Extremity Wounds*; 4(3):171-82.
- Grundy SM, Cleeman JI, Merz CN, et al., (2004).** National Heart, Lung, and Blood Institute. American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Circulation*; 110(2):227–239.

References

- Haffner SM (1998).** Management of dyslipidemia in adults with diabetes (technical review). *Diabetes Care*; 21:160–178.
- Haffner SM, Lehto S, Ronnema T, et al., (1998).** Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior MI. *N Engl J Med*; 339:229–234.
- Haffner SM, Mykkanen L, Festa A, et al., (2000).** Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. *Circulation*; 101:975–980.
- Hamalainen H, Ronnema T, Halonen JP, et al., (1996).** Factors predicting lower extremity amputations in patients with type 1 or type 2 diabetes mellitus: A population-based 7-year follow-up study. *J Int Med* 246:97–103.
- Harati Y, Gooch C, Swenson M, et al., (1998).** Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. *Neurology*; 50(6):1842–1846.
- Harpaz D, Gottlieb S, Graff E, et al., (1998).** Effects of aspirin treatment on survival in non-insulin dependent diabetic patients with coronary artery disease. Israeli Bezafibrate Infarction Prevention Study Group. *Am J Med*; 105:494–499.
- Hellweg R and Hartung HD (1990).** Endogenous levels of nerve growth factor (NGF) are altered in experimental diabetes mellitus: a possible role for NGF in the pathogenesis of diabetic neuropathy. *J Neurosci Res*; 26:258–267.
- Hennis AJJ, Fraser HS, Jonnalagadda R, et al., (2004).** Explanations for the high risk of diabetes-related amputation in a Caribbean population of black African descent and potential for prevention. *Diabetes Care*; 27(11): 2636–2641.
- Hill SL, Holtzman GI, and Buse R (1999).** The effects of peripheral vascular disease with osteomyelitis in the diabetic foot. *Am J Surg*; 177 (4):282–6.
- Hirsch AT, Criqui MH, Treat-Jacobson D., et al (2001).** Peripheral arterial disease detection, awareness, and treatment in primary care. *JAMA*; 286:1317–1324.

References

- Hollingshead TS (1991).** Pathophysiology and treatment of diabetic foot ulcer. *Clin Podiatr Med Surg*; 8 (4):843-55.
- Hovind P, Tarnow L, Rossing K, et al., (2003).** Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. *Diabetes Care*; 26:1258– 64.
- Huang Y, et al., (2001).** Oxidized LDL differentially regulates MMP-1 and TIMP-1 expression in vascular endothelial cells. *Atherosclerosis*; 156:119–125.
- Huijberts MS, Schaper NC, and Schalkwijk CG (2008).** Advanced glycation end products and diabetic foot disease. *Diabetes Metab Res Rev*; 24 (Suppl. 1):S19–S24.
- Hulthe J, Bokemark L, and Fagerberg B (2001).** Antibodies to oxidized LDL in relation to intima-media thickness in carotid and femoral arteries in 58 year-old subjectively clinically healthy men. *Arterioscler Thromb Vasc Biol*; 21:101–107.
- Hunt D (2002).** Using evidence in practice. Foot care in diabetes. [Review] [31refs]. *Endocrinology & Metabolism Clinics of North America*; 31(3):603 -11.
- Hutton WC and Dhanendran M (1981).** The mechanics of normal and hallux valgus feet—a quantitative study. *Clin Orthop Res*;157:7–13.
- Hutton W and Stokes I (1991).** The mechanics of the foot. In: Klenerman L, Ed. *The Foot and Its Disorders*; Oxford, England: Blackwell Scientific : 11 25.
- International Expert Committee (2009).** International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. *Diabetes Care*; 32:1327– 1334.
- James RW and Pometta D (1991).** The distribution profiles of very low and low density lipoproteins in poorly controlled male, type 2 (non insulin- dependent) diabetic patients. *Diabetologia*; 34:246–252.
- Jeffcoate WJ (2005).** The incidence of amputation in diabetes. *Acta Chir Belg*; 105:140-144.
- Jeffcoate WJ and Lipsky BA (2004).** Controversies in diagnosing and managing osteomyelitis of the foot in diabetes. *Clin Infect Dis*; 39(suppl, 2):S115 S122.
-

References

- Judzewitsch RG, Jaspan JB, Polonsky KS, et al., (1983).** Aldose reductase inhibition improves conduction velocity in diabetic patients. *N Engl J Med* 308:119–125.
- Kamei N, Yamane K, Nakanishi S, et al., (2005).** Effectiveness of Semmes Weinstein monofilament examination for diabetic peripheral neuropathy screening. *J Diabetes Complications*; 19:47-53.
- Kastrup J, Angelo H, Petersen P, et al., (1986).** Treatment of chronic painful neuropathy with intravenous lidocaine infusion. *Br Med J*; 292:173.
- Keith ND, Michael SK, Samy S et al., (2003).** Effects of duration and age at onset of type 1 diabetes on preclinical manifestations of nephropathy. *American Diabetes Association. Diabetes*; 52: 1818-1824.
- Kihara J, Schmelzer JD, Poduslo JF, et al., (1991).** Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology and oxygen free radicals. *Proc Natl Acad Sci USA*; 88:6107–6111.
- Knox RC, Dutch W, Blume P, et al., (2000).** Diabetic Foot Disease. *Int J Angiology*; 9:1-6.
- Koya D and King GL (1998).** Protein kinase C activation and the development of diabetic complications. *Diabetes*; 47:859–866.
- Kranke P, Bennett M, et al., (2004).** Hyperbaric oxygen therapy for chronic wounds. *Cochrane Database Syst Rev*; 2:CD004123.
- Kravos A and Bunic-Sotosek K (2009).** Ankle-brachial index screening for peripheral artery disease in asymptomatic patients between 50 and 70 years of age. *J Int Med Res*; 37(5):1611–9.
- Krolewski AS, Warram JH, Rand Li, et al., (1987).** Epidemiologic approach to the etiology of type I diabetes mellitus and its complications. *N Engl J Med*; 317:1390–1398.
- Kumar S, Ashe HA, Fernando DJS, et al., (1994).** The prevalence of foot ulceration and its correlates in type 2 diabetic patients: a population-based study. *Diabet Med*; 11:480–484.
- Landsman AS, Meaney DF, Cargill II RS, et al., (1995).** High strain tissue deformation. A theory on the mechanical etiology of diabetic foot ulcerations. *J Am Podiatr Assoc* 1995;85:519–527.
-

References

- Lavery LA, Armstrong DG, Wunderlich RP, et al., (2006). Risk factors for foot infection in individuals with diabetes. *Diabetes Care*; 29(6): 1288-93.
- Lavery LA, Armstrong DG, Wunderlich RP, et al., (2003). Predictive value of foot pressure assessment as part of a population-based diabetes disease management program. *Diabetes Care*; 26(4):1069–1073.
- Lavery Leal (2004). Options for Off-Loading the Diabetic Foot. *Advances in Skin Wound Care*; 17(May):181-186.
- Lawrence JA, Kim D, Kent KC, et al., (1995). Lower extremity spiral CT angiography versus catheter angiography. *Radiology*; 194(3):903–908.
- Lazzarini L, Lipsky BA, et al., (2005). Antibiotic treatment of osteomyelitis: What have we learned from 30 years of clinical trials? *Int J Infect Dis*; 9(3):127–138.
- Lee J, Lu M, Lee V, et al., (1993). Lower extremity amputation: Incidence, risk factors, and mortality in the Oklahoma Indian Diabetes Study. *Diabetes*; 42:876–882, 1993.
- Lemaster JW, Reiber GE, Smith DG, et al., (2003). Daily weight-bearing activity does not increase the risk of diabetic foot ulcers. *Med Sci Sports Exerc*; 35(7): 1093–1099.
- Lesser H, Sharma U, LaMoreaux L, et al., (2004). Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. *Neurology*; 63(11):2104–2110.
- Levin M.E (1996). Foot lesions in patients with diabetes mellitus. *Endocrin. Metab. Clin. NortL Am.*25:447-462.
- Libby P (1995). Molecular bases of the acute coronary syndromes. *Circulation*; 91:2844–2850.
- Lipsky BA, Armstrong DG, et al., (2005). Ertapenem versus piperacillin/ tazobactam for diabetic foot infections (SIDESTEP): Prospective, randomized, controlled, double-blinded, multicentre trial." *Lancet*; 366 (9498):1695–1703.
- Lipsky BA, Berendt AR, et al., (2004). IDSA Guidelines: Diagnosis and treatment of diabetic foot infections. *Clin Infect Dis*; 39:885–910.
- Lipsky BA, Pecoraro RE, Larson SA, et al., (1990). Outpatient management of uncomplicated lower-extremity infections in diabetic patients. *Arch Intern Med*; 150:790–797.
-

References

- Litzelman DK, Slemenda CW, Langefeld CD, et al., (1993).** Reduction of lower extremity clinical abnormalities in patients with non-insulin-dependent diabetes mellitus. A randomized, controlled trial. *Ann Intern Med*; 119(1):36–41.
- Lopes-Virella MF, et al., (1997).** The uptake of LDL-IC by human macrophages: Predominant involvement of the FcγRI. *Atherosclerosis*; 135:161–170.
- Maggi E, et al., (1994).** LDL oxidation in patients with severe carotid atherosclerosis: A study of in vitro and in vivo oxidation markers. *Arterioscler Thromb*; 14:1892–1899.
- Malgrange D, Richard JL, and Leymarie F (2003).** Screening diabetic patients at risk for foot ulceration. A multi-centre hospital-based study in France. *Diabetes Metab*; 29(3):261–268.
- Malik RA (1997).** The pathology of diabetic neuropathy. *Diabetes*; 46 (Sup- pl.2):S50–S53.
- Malik RA, Newrick PG, Sharma AK, et al., (1998).** Microangiopathy in human diabetic neuropathy: relationship between capillary abnormalities and the severity of neuropathy. *Diabetologia*; 32:92–102.
- Malik RA, Williamson S, Abbott CA, et al., (1998).** Effect of the angiotensin converting enzyme inhibitor trandolapril on human diabetic neuropathy: a randomized controlled trial. *Lancet*; 352:1978–1981.
- Malmberg K (1997).** Prospective randomized study of intensive insulin treatment on long term survival MI in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus Glucose Infusion in Acute MI) Study Group. *BMJ*; 314:1512–1515.
- Mason J, O’Keeffe C, McIntosh A, et al., (1999).** A systematic review of foot ulcer in patients with type 2 diabetes mellitus: I. Prevention. *Diabet Med*; 16:801–12.
- Marso SP and Hiatt WR (2006).** Peripheral arterial disease in patients with diabetes. *J Am Coll Cardiol*; 47:921–929.
- Marx N, et al., (2003).** Antidiabetic PPAR-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. *Arterioscler Thromb Vasc Biol*; 23:283–288.
-

References

- Marx N, et al., (2003).** Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary heart disease. *Circulation*; 107: 1954–1957.
- Max MB, Culnane M, Schafer SC, et al., (1987).** Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. *Neurology*; 37:596–598.
- Mayfield JA, Reiber GE, Nelson RG, et al., (1996).** A foot risk classification system to predict diabetic amputation in Pima Indians. *Diabetes Care*; 19(7):704–709.
- Mayser P, Hensel J, et al., (2004).** Prevalence of fungal foot infections in patients with diabetes mellitus type 1: Underestimation of moccasin type tinea. *Exp Clin Endocrinol Diabetes*; 112(5):264–268.
- Meigs JB, Mittleman MA, Nathan DM, et al., (2000).** Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring .
- Morgan et al., (2000).** The prevalence of multiple diabetes-related complications. *diabetic medicine*, 17:146 -151.
- Moons AH, Levi M, and Peters RJ (2002).** Tissue factor and coronary heart disease. *Cardiovasc Res*; 53:313–325.
- Moss SE, Klein R, and Klein BE (1999).** The 14-year incidence of lower extremity amputations in a diabetic population: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. *Diabetes Care*; 22(6):951–959.
- Moss SE, Klein R, and Klein BEK (1992).** The prevalence and incidence of lower extremity amputation in a diabetic population. *Arch Intern Med*; 152:610–616.
- Muller LM, Gorter KJ, et al., (2005).** Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. *Clin Infect Dis*; 41(3):281–288.
- Mueller MJ, Minor SD, Diamond JE, et al., (1995).** Relationship of foot deformity to ulcer location in patients with diabetes mellitus. *Phys Ther*; 70:356–362.
- Nabarro JDN (1988) .** Diabetes in the United Kingdom: some facts and figures. *Diabet Med*; 9: 816-22.
- Narayan KM, Koch DD, and Phillips LS (2010).** Glucose-independent, black white differences in hemoglobin A1c levels:

References

- a cross sectional analysis of 2 studies. *Ann Intern Med*; 152:770–777.
- Nather A, Bee CS, Huak CY, et al., (2008).** Epidemiology of diabetic foot problems and predictive factors for limb loss. *J Diabetes Complications*; 22(2): 77-82.
- Navab M, et al., (1991).** Monocyte transmigration induced by modification of low density lipoprotein in co-cultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. *J Clin Invest*; 88:2039– 2046.
- Nawroth PP, et al., (1986).** Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin-1. *J Exp Med* 165: 1363–1375.
- Nelson EA, O'Meara S, Golder S, et al., (2006).** Systematic review of antimicrobial treatments for diabetic foot ulcers. *Diabet Med* (in press).
- Nester CJ (1998).** Review of literature on the axis of rotation at the subtalar joint. *Foot*; 8:111–118.
- Nievelstein PFEM, et al., (1991).** Lipid accumulation in rabbit aortic intima 2 hours after bolus infusion of LDL: A deep etch and immunolocalization study of rapidly frozen tissue. *Arterioscler Thromb*; 11:1795–1805.
- Nissen SE (2002).** Application of intravascular ultrasound to characterize coronary artery disease and assess the progression or regression of atherosclerosis. *Am J Cardiol*; 89(4A):24B–31B.
- Ogunlade SO, Alonge TO, Omololu AB, et al., (2002).** Major limb amputation in Ibadan . *Afr J Med Med Sci*; 31(4):333-6.
- Oyibo SO, Jude EB, et al., (2001).** A comparison of two diabetic foot ulcer classification systems: The Wagner and the University of Texas wound classification systems. *Diabetes Care*; 24(1):84–88.
- Özmen B and Boyuada S (2003).** The relationship between self monitoring of blood glucose control and glycosylated haemoglobin in patients with type 2 diabetes with and without diabetic retinopathy. *Journal of Diabetes and its complications*; 17(3): 128-134.
- Paivi TR (2002).** Risk factors for microvascular complications in diabetes. Philadelphia. Hanley. Belfus; 3rd: 13-31.
-

References

- Pan XR et al., (1997).** Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. *Diabetes Care*; 20: 537–544.
- Paraskevas KI, Baker DM, Pompella A, et al., (2008).** Does diabetes mellitus play a role in restenosis and patency rates following lower extremity peripheral arterial revascularization? A critical overview. *Ann Vasc Surg*; 22:481–491.
- Patout CA, Birke JA, Horswell R, et al., (2001).** Effectiveness of a comprehensive diabetes lower-extremity amputation prevention program in a predominantly low-income African-American population. *Diabetes Care*; 23:1339-42.
- Pickup JC and Williams G (2003).** "The diagnosis and classification of diabetes and impaired glucose regulation" In *Text Book of Diabetes*. Third Edition. Oxford: Black-well science; 12: 1-5.
- Pinzur MS, Pinto MA, et al., (2003).** Controversies in amputation surgery. *Instr Course Lect*; 52:445–451.
- Pinzur MS, Slovenkai MP, et al., (2005).** Guidelines for diabetic foot care: Recommendations endorsed by the Diabetes Committee of the American Orthopaedic Foot and Ankle Society. *Foot Ankle Int*; 26(1):113–119.
- Pitei DL, Foster A, and Edmonds M (1999).** The effect of regular callus removal on foot pressures. *J Foot Ankle Surg*; 38:251-255.
- Plank J, Haas W, Rakovac I, et al (2003).** Evaluation of the impact of chiropodist care in the secondary prevention of foot ulcerations in diabetic subjects. *Diabetes Care*; 26:1691-1695.
- Prompers L, Schaper N, Apelqvist J, et al., (2008).** Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIALE Study. *Diabetologia*; 51(5): 747-55.
- Rai NK, Tripathi K, Sharma D, et al., (2005).** Apoptosis: a basic physiologic process in wound healing. [Review] [63 refs]. *International Journal of Lower Extremity Wounds*; 4(3):138-44.
- Ramsey, Newton, Blough, et al., (1999).** Incidence, outcomes, and cost of foot ulcers in patients with diabetes. *Diabetes Care*; 22:382–387.
-

References

- Rauwerda JA (2004).** Surgical treatment of the infected diabetic foot. *Diabetes Metab Res Rev*; 20(suppl 1):S41–S44.
- Reddy VY, Zhang QY, and Weiss SJ (1995).** Pericellular mobilization of the tissue-destructive cysteine proteinases, cathepins B, L, and S, by human monocyte-derived macrophages. *Proc Natl Acad Sci U S A*; 92:3849–3853.
- Reiber GE (2001).** Epidemiology of foot ulcers and amputations in the diabetic foot. In: *The Diabetic Foot*, pp 13-32, edited by JH Bowker and MA Pfeifer, Mosby, St. Louis.
- Reiber GE, Pecoraro RE, and Koepsell TD (1992).** Risk factors for amputation in patients with diabetes mellitus. *Ann Intern Med*; 117(2):97–105.
- Reiber G, Vileikyte L, Boyko E., et al (1999).** Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings. *Diabetes Care*; 22(1):157–162.
- Reiber GE, Boyko EJ, and Smith DG (1995).** Lower extremity foot ulcers and amputations in diabetes. In: *Diabetes in America*, 2nd ed, pp 409-427, edited by MI Harris, C Cowie, and MP Stern, NIH Publication No. 95-1468.
- Reiber GE, Pecoraro RE, and Koepsell TD (1992).** Risk factors for amputation in patients with diabetes mellitus: A case control study. *Ann Intern Med* 117:97–105.
- Reiber GE, Smith DG, Wallace C, et al., (2002).** Effect of therapeutic footwear on foot reulceration in patients with diabetes: a randomized controlled trial. *JAMA*; 287:2552-2558.
- Reiber GE, Vileikyte L, Boyko EJ, et al., (1998).** Causal pathways for incident lower extremity ulcers in patients with diabetes from two settings. *Diabetes Care*; 22:157-162.
- Resnick HE, Carter EA, Sosenko JM, et al., (2004).** Incidence of lower-extremity amputation in American Indians: the Strong Heart Study. *Diabetes Care*; 27:1885-1891.
- Reaven GM (1995).** Pathophysiology of insulin resistance in human disease. *Physiol Rev* ;75:473–486.
- Robertson DD, Mueller MJ, Smith KE et al., (2002).** Structural changes in the forefoot of individuals with diabetes and a prior plantar ulcer. *J Bone Joint Surg Am*; 84A:1395-1404.
-

References

- Ross R, et al., (1990).** Localization of PDGF-B protein in macrophages in all phases of atherogenesis. *Science*; 248:1009–1012.
- Said G, Slama G, and Selva J (1983).** Progressive centripetal degeneration of axons in small-fibre type diabetic polyneuropathy. A clinical and pathological study. *Brain*;106:791.
- Salvana J, Rodner C, et al., (2005).** Chronic osteomyelitis: Results obtained by an integrated team approach to management. *Conn Med*; 69(4):195–202.
- Sapico FL, Witte JL, Canawati HN, et al., (1984).** The infected foot of the diabetic patient: Quantitative microbiology and analysis of clinical features. *Rev Infect Dis*; 6 (suppl 1):171–176.
- Schaub FJ, et al., (2000).** Fas/FADD-mediated activation of a specific program of inflammatory gene expression in vascular smooth muscle cells. *Nature Med*; 6:790–796.
- Schmidt AM, Yan SD, Wautier JL, et al., (1999).** Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. *Circ Res*; 84:489–497.
- Schwartz D, et al (1994).** The role of a *gro* homologue in monocyte adhesion to endothelium. *J Clin Invest* 94:1968–1973.
- Schwenke DC and Carew TE (1989).** Initiation of atherosclerotic lesions in cholesterol-fed rabbits: II. Selective retention of LDL vs selective increases in LDL permeability in susceptible sites of arteries. *Arteriosclerosis*; 9: 908–918.
- Selby JV and Zhang D (1995):** Risk factors for lower extremity amputation in persons with diabetes. *Diabetes Care*; 18(4):509–516.
- Senneville E (2005).** Antimicrobial interventions for the management of diabetic foot infections. *Expert Opin Pharmacother*; 6(2): 263–273.
- Sentohnik DE and Eliopoulos GM (1994).** Infection and diabetes. In Kahn CR, Weir GC (eds): *Joslin's Diabetes Mellitus*, 13th ed. Philadelphia: Lea & Febiger; pp 867–888.
- Shah BR and Hux JE (2003).** Quantifying the risk of infectious diseases for people with diabetes. *Diabetes Care*; 26(2):510–513.
- Shaw JE and Boulton AJM (1997).** The pathogenesis of diabetic foot problems. An overview. *Diabetes*; 46 (Suppl 2):S58–S61.
-

References

- Singh N, Armstrong DG and Lipsky BA (2005).** Preventing foot ulcers in patients with diabetes. [Review] [128 refs]. *JAMA*; 293(2):217-28.
- Sobel E, Levitz SJ, and Caselli MA (1999).** Orthoses in the treatment of rear foot problems. [Review] [151 refs]. *Journal of the American Podiatric Medical Association*; 89(5):220-33.
- Solagberu BA (2001).** The scope of amputations in a Nigerian teaching hospital. *Afr J Med Med Sci*; 30(3):225-7.
- Sperling MA (2000).** "Diabetes mellitus" In Nelson textbook of pediatrics. Behrman RE, Kliegman RM and Jenson HB. (eds). 16th edition WB saunders; 1767-1791.
- Steinberg HO, Chaker H, Leaming R, et al., (1998).** Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. *J Clin Invest*; 97:2601–2610.
- Strauss MB and Aksenov IV (2005).** Evaluation of diabetic wound classifications and a new wound score. [Review] [20 refs]. *Clinical Orthopaedics & Related Research*; 439:79-86.
- Sulimani R, Famuyiwa oo, and Mekki (1991).** Patter of diabetic foot lesions in Suadia Arebia. Experience from King Khalid Univer-sity Hosapital, Riyadh, *Annals Saudi Medicine*, 11:47-50.
- Sumpio BE, Lee T, et al., (2003).** Vascular evaluation and arterial reconstruction of the diabetic foot. *Clin Podiatr Med Surg*; 20(4): 689- 708.
- Sumpio BE. (2000).** Foot ulcers. *N Engl J Med*; 343:787-793. *Neurol*; 21:527–533.
- Suzuki E, Kashiwagi A, Hidaka H, et al., (2000).** 1H- and 31P-magnetic resonance spectroscopy and imaging as a new diagnostic tool to evaluate neuropathic foot ulcers in Type II diabetic patients. *Diabetologia*; 43:165–172.
- Tan JS, Friedman NM, Hazelton-Miller C, et al., (1995).** Can aggressive treatment of diabetic foot infections reduce the need for above ankle amputation? *Clin Infect Dis*; 23:286–291.
- Tan JS and Joseph WS (2004).** Common fungal infections of the feet in patients with diabetes mellitus. *Drugs Aging*; 21(2):101–112.
- Tedgui A and Mallat Z (2001).** Apoptosis as a determinant of atherothrombosis. *Thromb Haemost*; 86:420–426.
-

References

- Tentolouris N, Petrikos G, et al., (2006).** Prevalence of methicillin resistant *Staphylococcus aureus* in infected and uninfected diabetic foot ulcers. *Clin Microbiol Infect*; 12(2):186–189.5
- Tesfaye S, Chaturvedi N, Eaton SEM, et al., (2005).** Vascular risk factors and diabetic neuropathy. *New Engl J Med*; 352:341–350.
- Tesfaye S, Harris N, Wilson RM, et al., (1992).** Exercise induced conduction velocity increment: a marker of impaired nerve blood flow in diabetic neuropathy. *Diabetologia*; 35:155–159.
- Tesfaye S, Malik R, Harris N, et al., (1996).** Arteriovenous shunting and proliferating new vessels in acute painful neuropathy of rapid glycemic control (insulin neuritis). *Diabetologia*; 39:329–335.
- Tesfaye S, Watt J, Benbow SJ, et al., (1996).** Electrical spinal cord stimulation for painful diabetic peripheral neuropathy. *Lancet*; 348:1696–1701.
- The Diabetes Control and Complications Trial Research Group (1993).** The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med*; 329:977–986.
- Thomas PK (1973).** Metabolic neuropathy. *J R Coll Physicians Lond*; 7:154–160.
- Tisi PV and Callam MJ (2004).** Type of incision for below knee amputation. [Review] [22 refs]. *Cochrane Database of Systematic Reviews* (1):CD003749.
- Tse WY and Kendall M (1994).** Is there a role for beta-blockers in hypertensive diabetic patients? *Diabetic Medicine*; 11:137–144 (review).
- Turk Z, et al., (2001).** Detection of auto antibodies against advanced glycation end products and AGE-immune complexes in serum of patients with diabetes mellitus. *Clin Chim Acta*; 303:105–115. *J Clin Invest* 105:1731–1740.
- Turner RC (1998).** The U.K. Prospective Diabetes Study. A review. *Diabetes Care*; 21(Suppl):C35–C38.
- Tyrrell W (1999).** Orthotic intervention in patients with diabetic.
- United Kingdom Prospective Diabetes Study Group (1998).** Effect of intensive blood-glucose control with metformin on complicati-
-

References

- ons in overweight patients with type 2 diabetes (UKPDS 34). *Lancet*; 352:854-865.
- United Kingdom Prospective Diabetes Study Group (1998).** Efficacy of atenolol and captopril in reducing risk of macrovascular complications in type 2 diabetes, UKPDS39. *BMJ*; 317: 713-720.
- United Kingdom Prospective Diabetes Study (1998).** Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes: UKPDS 38. *BMJ*; 317: 703-713.
- United Kingdom Prospective Diabetes Study Group (1998).** Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. *Lancet*; 352:837-853.
- Valk GD, Kriegsman DM, and Assendelft WJ (2002).** Patient education for preventing diabetic foot ulceration: a systematic review. *Endocrinol Metab Clin North Am*; 31:633-658.
- Van Acker K (2000).** The Diabetic Foot. A Challenge for Policy-Makers and Health Care Professionals. Department of Medicine, University of Antwerp, Antwerp.
- Van Schie CHM (2000).** Joint mobility and foot pressure measurements in Asian and European diabetic patients: clues for difference in foot ulcer prevalence (abstract). *Diabetes* 49(Suppl 1):A197
- Veves AGJMLFW (2002).** The Diabetic Foot Medical and Surgical Management. Humana Press.
- Viberti G, Mogensen CE, Groop LC, et al., (1994).** Effect of captopril on progression to clinical proteinuria in patients with insulin diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study. *J Am Med Assoc*; 271:275-279.
- Vincent DG, Salles-Cunha SX, Bernhard VM, et al., (1983).** Noninvasive assessment of toe systolic pressures with special reference to diabetes mellitus. *J Cardiovasc Surg*; 24(1):22-28.
- Virella G, et al., (1995).** Activation of human monocyte-derived macrophages by immune complexes containing low-density lipoprotein. *Clin Immunol Immunopathol*; 75:179-189.
- Virella G, et al., (2002).** Proatherogenic and pro-inflammatory properties of immune complexes prepared with purified
-

References

- human oxLDL antibodies and human oxLDL. *Clin Immunol*; 105:81–92.
- Virella G, et al., (2003).** Autoimmune response to advanced glycosylation end products of human low-density lipoprotein. *J Lipid Research*; 44:487–493.
- Virella G and Lopes-Virella MF (2003).** Lipoprotein autoantibodies: Measurement and significance. *Clin Diag Lab Immunol*; 10: 499–505.
- Virella G and Tsokos G(2002).** Immune complex diseases. In G. Virella (ed): *Medical Immunology*, 5th ed. New York: Marcel Dekker; pp 453– 471.
- Vlassara H, Brownlee M, and Cerami A (1984).** Accumulation of diabetic rat peripheral nerve myelin by macrophages increases with the presence of advanced glycosylation end products. *J Exp Med*; 160:197.
- Walters DP, Catling W, and Mullee MA (1992).** The distribution and severity of diabetic foot disease: a community study with comparison to a non-diabetic group. *Diabet Med*; 9: 354-8.
- Wang JC, Le AW, and Tsukuda RK (2002).** A new technique for Charcot's foot reconstruction. *J Am Podiatr Med Assoc*; 92:429-436.
- Wernick J and Volpe RG (1996).** Lower extremity function and normal mechanics, In *Clinical biomechanics of the lower extremities* (Valmassy RL, ed.), Mosby Year Book, St Louis, pp. 2–57.
- Wheat LJ, Allen SD, Henry M, et al., (1986).** Diabetic foot infections: Bacteriologic analysis. *Arch Intern Med*; 146:1935–1940.
- Williams DT, Hilton JR, et al., (2004).** Diagnosing foot infection diabetes. *Clin Infect Dis*; 39(suppl 2):S83–S836.
- Witte DR, Tesfaye S, Chaturvedi N, et al., (2005).** Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus. *Diabetologia*; 48:164 171.
- World Health Organization (1999).** Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO Consultation. Part 1: diagnosis and classification of diabetes mellitus. Geneva, (WHO/NCD/NCS/99.2).
-

References

- World Health Organization (2004).** Global strategy on diet, physical activity and health. Geneva, World Health Organization. (Fifty-seventh World Health Assembly, WHA57.17).
- Wu S and Armstrong DG (2005).** Risk assessment of the diabetic foot and wound. [Review] [63 refs]. *International Wound Journal*; 2(1):17-24.
- Wu SC and Armstrong DG (2006).** The role of activity, adherence, and off-loading on the healing of diabetic foot wounds. [Review] [40 refs]. *Plastic & Reconstructive Surgery*; 117(7 Suppl):248S-253S.
- Yokoyama H, Okudaira M, Otani T, et al., (2000).** Higher incidence of diabetic nephropathy in type 2 than in type 1 diabetes in early onset diabetes in Japan. *Kidney Int*; 58:302– 11.
- Young MJ, Boulton AJM, Macleod AF, et al., (1993).** A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital population. *Diabetologia*; 36: 150-4.
- Young MJ, Cavanagh PR, Thomas G, et al., (1992).** The effect of callus removal on dynamic plantar foot pressures in diabetic patients. *Diabet Med*; 9:55-57.
- Zatz R and Brenner BM (1986).** Pathogenesis of diabetic microangiopathy. The hemodynamic view. *Am J Med*; 80:443–453.
- Zeigler D, Hanefeld M, Ruhnau KJ, et al., (1995).** Treatment of symptomatic diabetic peripheral neuropathy with antioxidant alpha-lipoic acid: a 3-week multicentre randomised controlled trial (ALADIN Study). *Diabetologia*; 38:1425–1433.
- Ziemer DC, Kolm P, Weintraub WS, et al., (2010).** Prevalence of diabetes and high risk for diabetes using Hb A1C criteria in the U.S. population in 1988–2006. *Diabetes Care*; 33: 562–568
- Zimmet P, Boyko EJ, Collier GR, et al., (1999).** Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players; 892:25–44.
- Zochodone DW (2008).** Diabetic polyneuropathy. an update. *Curr Opin Neurol*; 21:527–533.